A cancer study hailed this week as potentially revolutionary for the treatment of leukaemia is based on research undertaken by Weizmann Institute Prof. Zelig Eshhar.
An article in the journal Science Translational Medicine outlines how researchers from the University of Pennsylvania’s Abramson Cancer Center and the Perelman School of Medicine found that 27 out of 29 advanced leukaemia patients either went into remission, or saw their illness go away completely after their T-cells were modified genetically, a success rate of nearly 94 per cent.
In the study carried out at the Fred Hutchinson Cancer Research Center in Seattle, Wa. the cells were equipped with synthetic molecules able to destroy the tumour cells, particularly in cases of acute lymphoblastic leukaemia (ALL).
These results are not surprising for Prof. Eshhar, who pioneered the idea with a 1989 study published in the Proceedings of the National Academy of Sciences, in which he replaced the T-cell’s natural receptor with one of his choice, showing that T-cells can be engineered to attach to any entity. Eshhar won the Jewish state’s prestigious Israel Prize for his research in 2015.
“I’m not surprised to hear about the results,” he said, the Times of Israel reported. “In our lab, we cured many rats and mice of cancer. I have been saying for years that we could do this in people, as well.”
“I felt a great sense of satisfaction upon hearing the news,” added Eshhar. “The next task of my lab and others working on this is to expand it and try to attack other forms of cancer.”
He cautioned, however, that more work is needed before the treatment could really be seen as a cancer cure.
“Obviously much more work is needed,” he said. “One issue with this kind of therapy is that you have to develop specific T-cells for each kind of cancer. But studies like those are a great impetus to move forward with research. I believe the day will come when we will see many more cancers treated in this manner.”